Sign in

CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company

Dianthus Therapeutics, Inc. /DE/

Sign in to watch
Ticker
DNTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
929-999-4055
Business address
7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
Former names
Magenta Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$16,043,610
in 4 filings, $16.0M under 10b5-1 plans

Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Savitz Ryan −$11.2M EVP, CFO & CBO sold 100% of stake
  2. Randhawa Simrat −$2.5M EVP, Head of R&D sold 85% of stake
  3. CARR EDWARD −$2.0M CHIEF ACCOUNTING OFFICER sold 100% of stake
  4. Read Simon −$327K Director sold 100% of stake
Date Insider Transaction Shares Price Value Owned after
2018-06-25 ISACSON CHRISTINA K. Chief Business Officer Conversion +2,912 103,531
2018-06-25 ISACSON CHRISTINA K. Chief Business Officer Conversion · Series A Preferred Stock −6,670 0
2018-06-25 ISACSON CHRISTINA K. Chief Business Officer Conversion · Series B Preferred Stock −857 0
2018-06-25 Booth Bruce Director Conversion +4,746,876 4,843,625
2018-06-25 Booth Bruce Director Conversion · Series A Preferred Stock −12,061,496 0
2018-06-25 Booth Bruce Director Conversion · Series B Preferred Stock −204,339 0
2018-06-25 GV 2016 GP, L.L.C. 10% owner Conversion +3,339,137 3,339,137
2018-06-25 GV 2016 GP, L.L.C. 10% owner Conversion · Series A Preferred Stock −133,400 0
2018-06-25 GV 2016 GP, L.L.C. 10% owner Conversion · Series B Preferred Stock −8,494,864 0
2018-06-25 BONNEY MICHAEL W Director Conversion +21,847 215,346
2018-06-25 BONNEY MICHAEL W Director Conversion · Series A Preferred Stock −50,025 0
2018-06-25 BONNEY MICHAEL W Director Conversion · Series B Preferred Stock −6,429 0
2018-06-25 Albers Jeffrey W. Director Conversion +4,152 4,152
2018-06-25 Albers Jeffrey W. Director Conversion · Series C Preferred Stock −10,729 0
2018-06-25 BYERS BLAKE Director Conversion +3,339,137 3,339,137
2018-06-25 BYERS BLAKE Director Conversion · Series A Preferred Stock −133,400 0
2018-06-25 BYERS BLAKE Director Conversion · Series B Preferred Stock −8,494,864 0
2018-06-25 DAVIS JOHN C. JR Chief Medical Officer Conversion +8,304 8,304
2018-06-25 DAVIS JOHN C. JR Chief Medical Officer Conversion · Series C Preferred Stock −21,459 0
2018-06-25 GARDNER JASON See Remarks Conversion +25,719 292,990

Page 23 of 24 · 470 trades